EGFR and non-small cell lung carcinoma: Hence, our findings convincingly reveal a previously undiscovered connection between TRPM2 modulation and response of EGFRm NSCLC cells to osimertinib and likely other EGFR‐TKIs and also suggest a novel strategy for overcoming acquired resistance to osimertinib and other third generation EGFR‐TKIs via targeting TRPM2.